{"schema_version":"secwatch.filing_event.v1","accession":"0000719135-24-000013","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.743260+00:00","generated_at":"2026-06-04T10:41:52.370373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q4 revenue up 16% to $14.7M; net loss widens to $9.6M; FY2024 guidance implies potential revenue decline","bullets":["Q4 2023 Advanced Energy revenue $12.1M (+15% YoY); net loss $9.6M ($0.28/shr) vs $6.0M ($0.17) a year ago.","Full year 2023 total revenue $52.3M (+18%); net loss improved to $18.7M ($0.54/shr) from $23.2M ($0.67) in 2022.","FY2024 guidance: revenue $49.7M-$52.9M (down 5% to up 1%); net loss $24.3M-$26.5M, wider than 2023's $18.7M loss.","New $45M Perceptive credit facility closed Nov 2023; initial $37.5M funded, used to repay MidCap and $2.7M in fees.","Appointed Matthew Hill as CFO effective Dec 4, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000719135-24-000013","json":"https://secwatch.observer/filing/0000719135-24-000013.json","markdown":"https://secwatch.observer/filing/0000719135-24-000013.md","text":"https://secwatch.observer/filing/0000719135-24-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/apyx-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:41:52.370373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"145ccb55557d8ad66199be2f32b3f3c604dcb959","claim":"Apyx Medical Corp reported year ended December 31, 2023 results: revenue $52.3 million, net income Net loss attributable to stockholders of $18.7 million. Guidance initiated.","evidence_excerpt":"or 59%, year-over-year. • Adjusted EBITDA loss of $4.7 million, an increase of $0.6 million, or 14%, year-over-year. Full Year 2023 Financial Summary : • Total revenue of $52.3 million, an increase of 18% year-over-year. ◦ Advanced Energy revenue of $43.4 million, an increase of 18% year-over-year. ◦ OEM revenue of $9.0 million, an increase of 16%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Revenue","value":"$52.3 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $18.7 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5ae2a0635677e943ba1f521322c0a5ac57e976b7","claim":"Apyx Medical Corp reported three months ended December 31, 2023 results: revenue $14.7 million, net income Net loss attributable to stockholders of $9.6 million.","evidence_excerpt":"full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary : • Total revenue of $14.7 million, an increase of 16% year-over-year. ◦ Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. ◦ OEM revenue of $2.5 million, an increase of 22%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/719135/000071913524000013/0000719135-24-000013-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Revenue","value":"$14.7 million"},{"label":"Net income","value":"Net loss attributable to stockholders of $9.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}